http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102304562-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2019-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102304562-B1 |
| titleOfInvention | IL6 single nucleotide polymorphism marker in gene for predicting risk of drug induced leukopenia and method for predicting risk of drug induced leukopenia using the same |
| abstract | The present invention relates to a composition for predicting the risk of developing leukopenia comprising a single nucleotide polymorphism marker in the IL6 gene, and a method for predicting the risk of developing leukopenia using the same. The single nucleotide polymorphism marker in the IL6 gene according to the present invention has a high correlation with the risk of developing leukopenia induced by drugs, particularly thiopurine-based drugs, and using this, leukemia, Crohn's disease, ulcerative colitis, or It is possible to effectively predict or diagnose patients with high sensitivity to leukopenia occurring during treatment with thiopurine-based drugs, such as organ transplantation, at an early stage, and through this, a patient-tailored patient that can achieve the optimal therapeutic effect by administering the appropriate drug to the patient treatment can be performed effectively. Furthermore, the single nucleotide polymorphism marker according to the present invention can be utilized in drug development research for the treatment of drug-induced leukopenia. |
| priorityDate | 2019-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.